Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies

Table 1 Efficacy of surgery for Barrett’s esophagus with intramucosal adenocarcinoma

Ref.	Type	n1	LNMrate	5-yr DFS or DSS	5-yr OS
Rice et al[97]	Retrospective	53	2%	-	77%
Liu et al[61]	Retrospective	53	-	100%	91%
Prasad et al[75]	Retrospective	46	8.6%	97%	95%
Pennathur et al[59]	Retrospective	29	7%	82%	73%
Wang et al[109]	Retrospective	60; T1a 32%; HGD 68%	-	-	88%
Sepesi et al[72]	Retrospective	25	0%	-	85%
Zehetner et al[96]	Retrospective	48	-	88%	94% (3 yr)
Hölscher et al[56]	Retrospective	70; SCC 29%	0%	-	87%
Leers et al[55]	Retrospective	75	1.3%	98%	82%
Pech et al[95]	Retrospective	38	-	100% (3.7 yr)	93%
Ngamruengphong et al[120]	Retrospective	671	-	-	76%
Lorenz et al[57]	Retrospective	42	8.7%	93.4%	91%
Newton et al[54]	Retrospective	303	3.6%	-	80%
Marino et al[121]	Retrospective	1317	-	-	79%
Semenkovich et al[74]	Retrospective	428; SCC 16%	8.7%	-	80%

¹Pure T1a cohort unless otherwise stated.

DFS: Disease free survival; DSS: Disease specific survival; HGD: High grade dysplasia; LNM: Lymph node metastasis; OS: overall survival; SCC: Squamous cell carcinoma.